araag2/HINT huggingface dataset:
Clinical trial NCT01043029 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: aleglitazar, pioglitazone
SMILES: CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >/= 18 years of age

          -  Diabetes mellitus, Type 2

          -  Moderately impaired kidney function

          -  Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at
             screening

          -  BMI 25-35

        Exclusion Criteria:

          -  Current or previous treatment with a thiazolidinedione

          -  Current or previous treatment with insulin

          -  Treatment with fibrates <3 months prior to screening

          -  History of renal disease other than diabetic nephropathy
Clinical trial NCT00104169 (phase 2, status: terminated)
Conditions: anemia, aging
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    no subject accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  70 years of age or older

          -  Diagnosed with anemia

          -  Hemoglobin level less than or equal to 11

          -  Able to perform most activities of daily living without restriction

        Exclusion Criteria:

          -  History of serious heart, liver or kidney disease

          -  Cancer treated within the last year except for skin cancer (excluding melanoma)

          -  Problems with your immune system

          -  Received Epoetin Alfa within the last year
Clinical trial NCT00262613 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: sodium pyruvate in 0.9% sodium chloride solution
SMILES: CC(=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Individuals with a clinical diagnosis of moderate to severe COPD, <70% predicted FEV1,
             and a stable pulmonary disease status.

        Exclusion Criteria:

          -  a. Pulmonary disease other than COPD

          -  b. Clinically significant cardiac disease including uncontrolled congestive heart
             failure and unstable angina

          -  c. Pregnancy

          -  d. Females of child bearing potential age not on adequate contraception or lactating

          -  e. Subjects receiving oral or IV corticosteroid treatment within one month of
             Screening Visit

          -  f. Less than 18 years of age and greater than 85 years of age

          -  g. Hospitalization within last 6 months due to acute exacerbation of air-way disease

          -  h. Subjects on escalating dose of immunotherapy

          -  i. Subjects with a clinically significant abnormal chest x-ray within past 12 months.

          -  j. Medication changes within 1 month

          -  k. Subjects who have participated in another investigation drug treatment study within
             the previous month.

          -  l. Subjects with a current history of alcohol abuse or recreational drug use.

          -  m. Subjects who have taken vitamins with anti-oxidant properties (E or C) or dietary
             supplements containing pyruvate within 24 hours prior to the screening visit.

          -  n. Subjects who use less than 4 puffs of Albuterol a day over the period between the
             Screening Visit and Visit 1.
Clinical trial NCT01041677 (phase 2, status: completed)
Conditions: obesity, nutritional and metabolic diseases, metabolic diseases, nutrition disorders, overweight
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, Z86.39, O99.280, O99.281, O99.282, O99.283, O99.284, O99.285, E66.3
Drugs: r256918, placebo, r256918
SMILES: COC(=O)[C@H](N1CCC(CC1)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)[C@H](N1CCC(CC1)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Liver fat content (HTGC) between 3% and 15%

          -  Obese defined as BMI between 30 and 50 kg/square meter

          -  Fasting plasma glucose < 7.0 mmol/liter

        Exclusion Criteria:

          -  History of Obesity with a known cause (eg. Cushings disease)

          -  Diabetes Mellitus

          -  Weight reducing diet or receiving drugs to treat obesity within 3 months prior to
             screening

          -  Significant change in smoking habits within 3 months before enrollment
Clinical trial NCT01156844 (phase 2, status: completed)
Conditions: persistent asthma
ICD codes: J45.30, J45.40, J45.50, J45.31, J45.32, J45.41, J45.42
Drugs: indacaterol, placebo to indacaterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of asthma and:

          -  Receiving daily treatment with inhaled corticosteroid in a regimen that has been
             stable for at least a month prior to screening

          -  FEV1 ≥50% and ≤90% of predicted normal at screening

          -  An increase of ≥12% and ≥200 mL in FEV1 over prebronchodilator value within 30 minutes
             after inhaling a total dose of albuterol/salbutamol of 360/400 MDI

        Exclusion Criteria:

          -  Smoking history of ≥ 10 years

          -  Patients with a diagnosis of COPD

          -  Patients who have been previously intubated for a severe asthma exacerbation/ attack

          -  Patients who have experienced a severe asthma attack/exacerbation requiring
             hospitalization in the 6 months prior to screening

          -  Patients who have had an emergency room visit for an asthma attack/exacerbation within
             6 weeks prior to screening

          -  Patients who have had a respiratory tract infection within 6 weeks prior to screening

          -  Patients with seasonal allergy whose asthma is likely to deteriorate during the study
             period

          -  Patients with Type I or uncontrolled Type II diabetes mellitus

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00115687 (phase 2, status: terminated)
Conditions: tobacco use disorder
ICD codes: Z72.0, P04.2
Drugs: placebo, 2 mg nicotine polacrilex
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1CCC[C@H]1C1=CN=CC=C1
Reason stopped: 
    efficacy rates did not show large enough differences between treatments
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient's gestational age is 26 weeks or less.

          -  Patient is at least 16 years of age.

          -  Patient is able to speak English or Spanish.

          -  Patient intends to carry to term.

          -  Patient has stable residence.

          -  Patient has smoked five or more cigarettes everyday for the past seven days.

        Exclusion Criteria:

          -  Evidence that the patient is pregnant with a fetus with a known congenital
             abnormality.

          -  Unstable medical problems (i.e., hyperthyroidism, temporomandibular joint disorder,
             pre-eclampsia, threatened abortion, hyperemesis gravidarum)

          -  Multiple Gestation

          -  Unstable psychiatric disorder

          -  Current drug or alcohol abuse or dependence
Clinical trial NCT00475865 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: teriflunomide, placebo (for teriflunomide), glatiramer acetate (ga)
SMILES: C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Definite MS diagnosis according to McDonald's criteria;

          -  Relapsing clinical course, with or without progression;

          -  Expanded Disability Status Scale [EDSS] less or equal to 5.5 (ambulatory);

          -  Stable dose of Glatiramer Acetate [GA] for at least 26 weeks prior to the screening
             visit;

          -  No onset of MS relapse in the preceding 60 days prior to randomization;

          -  Clinically stable for 4 weeks prior to randomization.

        Exclusion Criteria:

          -  Other chronic disease of the immune system, liver function impairment or chronic
             pancreatic disease;

          -  Pregnant or nursing woman;

          -  Alcohol or drug abuse;

          -  Use of cladribine, Mitoxantrone, or other immunosuppressant agents such as
             Azathioprine, Cyclophosphamide, Cyclosporin, Methotrexate or Mycophenolate before
             enrollment;

          -  Human immunodeficiency virus [HIV] positive status;

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00628212 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: teneligliptin 10mg, teneligliptin 20 mg, teneligliptin 40 mg, placebo
SMILES: [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who are 20 - 75 years old

          -  Patients who are under dietary management and taking therapeutic exercise for diabetes
             over 12 weeks before administration of investigational drug

          -  Patients whose HbA1c is 6.5 - 9.5%

          -  Patients who were not administered drugs prohibited for concomitant use within 12
             weeks before administration of investigational drug.

        Exclusion Criteria:

          -  Patients with type 1 diabetes, diabetes mellitus caused by pancreas failure, or
             secondary diabetes (Cushing disease, acromegaly, etc)

          -  Patients with Class III/IV heart failure symptoms according to New York Heart
             Association (NYHA) functional classification

          -  Patients with serious diabetic complications

          -  Patients who are habitual excessive alcohol consumption.

          -  Patients with severe hepatic disorder or severe renal disorder.

          -  Pregnant, lactating, and probably pregnant patients, and patients who can not agree to
             contraception
Clinical trial NCT01204372 (phase 2, status: completed)
Conditions: metastatic pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: gemcitabine - trastuzumab - erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic pancreatic adenocarcinoma confirmed by histology

          -  Tumor sample available

          -  Measurable lesion according to RECIST criteria

          -  Performance status ≥ 1

          -  Life expectancy > 3 months

          -  Hematology: Hb ≥ 9g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3

          -  Renal function: creatinine ≤ 1.5 x ULN

          -  Hepatic function: total bilirubin ≤ 2.5 x ULN, transaminases ≤ 5 x ULN

          -  Left ventricular ejection fraction (LVEF) ≥ 50%

          -  At least a 6-month delay between the end of any previous gemcitabine-based
             chemotherapy and diagnosis of metastases

          -  Social security

          -  Informed consent obtained prior to inclusion.

        Exclusion Criteria:

          -  Non metastatic advanced local disease

          -  Presence of cerebral metastases or symptomatic leptomeningeal carcinomatosis

          -  Others cancers except BBC and cervical cancer receiving curative treatment

          -  No previous treatment by Erlotinib or Trastuzumab

          -  Known severe hypersensitivity to Erlotinib, Trastuzumab, murine proteins or
             Gemcitabine

          -  Presence of significant co-morbidities

          -  Concomitant treatment with other experimental products or other anticancer therapies

          -  Breastfeeding or pregnant female, or patient of reproductive age not using adequate
             contraception

          -  Legal incapacity or limited legal incapacity
Clinical trial NCT01085045 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: pt003 mdi, pt005 mdi, placebo mdi, tiotropium bromide 18 μg (spiriva handihaler®), formoterol fumarate 12 μg (foradil® aerolizer®), pt001 mdi
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70

          -  A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT00429936 (phase 2, status: completed)
Conditions: geographic atrophy, dry age related macular degeneration
ICD codes: K14.1
Drugs: fenretinide
SMILES: C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  males or females, 50 to 89 years of age

          -  must have GA from AMD in one or both eyes

        Exclusion Criteria:

          -  GA due to any disease other than AMD (eg, drug-induced)
Clinical trial NCT00040469 (phase 2, status: terminated)
Conditions: sickle cell anemia, hemoglobinopathy, thalassemia
ICD codes: D56.0, D56.1, D56.3, D56.9, D56.2, D56.5, D57.40
Drugs: campath -1h, dilantin, busulfan, cyclophosphamide
SMILES: O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1, CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    accrual was slow and sporadic so the study was closed
  
Eligibility criteria:

        Inclusion:

          -  Patients with homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with
             an HLA genotypically identical donor.

          -  Patients with an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or
             hemoglobin Sb 0/+ and at least one of the following:

        Previous central nervous system vaso-occlusive episode with or without residual neurologic
        findings; Frequent painful vaso-occlusive episodes which significantly interfere with
        normal life activities and which necessitate chronic transfusion therapy; Recurrent SCD
        chest syndrome events which necessitate chronic transfusion therapy.

          -  Severe anemia which prevents acceptable quality of life and necessitates chronic
             transfusion therapy.

          -  The patient must have an HLA genotype identical donor.

          -  Between the ages of birth and 65 years.

          -  Women of childbearing potential must have a negative pregnancy test.

        Exclusion:

          -  Biopsy proven chronic active hepatitis or fibrosis with portal bridging.

          -  SCD chronic lung disease >/= stage 3.

          -  Severe renal dysfunction defined as creatinine clearance <40 ml/min/1.73 M2

          -  Severe cardiac dysfunction defined as shortening fraction <25%.

          -  HIV infection.

          -  Severe but unspecified chronic toxicity serious enough to detrimentally affect the
             patient's capacity to tolerate bone marrow transplant (BMT).

          -  Inadequate intellectual capacity to understand the nature and risk inherent in the BMT
             process and give informed consent (in the case of minors, this criteria must be
             fulfilled by the legal guardian).

          -  Pregnant, lactating or unwilling to use appropriate birth control.
Clinical trial NCT00414960 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: enzastaurin, placebo
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Sputum atypia participants with normal sputum cytology will be removed from the study)

          -  Metaplasia or dysplasia on at least one bronchoscopy specimen

          -  History of cigarette smoking ≥30 Pack Years

          -  Quit smoking ≥1 year prior to study entry

          -  Able to undergo bronchoscopy and helical computed tomography (CT) scanning of the
             chest

          -  Able to swallow tablets

        Exclusion Criteria:

          -  Blood clotting abnormalities

          -  Current smoking within the past 1 year

          -  Unwillingness to abstain from smoking while enrolled in the clinical trial or
             unwillingness to avoid significant second hand smoke exposure

          -  Evidence for lung cancer or carcinoma in situ

          -  Active cardiovascular disease

          -  Current illicit drug or alcohol abuse
Clinical trial NCT01302041 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: enzalutamide
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed prostate cancer (all stages) for whom androgen deprivation
             therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy)

          -  Asymptomatic from prostate cancer

          -  Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening

          -  PSA ≥ 2 ng/mL at screening

        Exclusion Criteria:

        Has previously or is currently receiving:

          -  Hormonal therapy with intent to treat prostate cancer

          -  Systemic glucocorticoids

          -  Chemotherapy with the intent to treat prostate cancer

          -  Opiate analgesics for pain from prostate cancer

          -  Radiation therapy for treatment of the primary tumor or metastases

          -  Has history of known or suspected brain or skull metastases or leptomeningeal disease

          -  Has history of seizure including febrile seizure or any condition that may predispose
             to seizure or history of loss of consciousness or transient ischemic attack

          -  Clinically significant cardiovascular disease
Clinical trial NCT00332163 (phase 2, status: completed)
Conditions: metastatic colorectal cancer, skin rash, skin toxicities, colon cancer, colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, R21, C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan, folfiri, pre-emptive skin treatment, reactive skin treatment
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, FC1=CNC(=O)NC1=O, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with unresectable metastatic adenocarcinoma of the colon or rectum that
             cannot, in the opinion of the investigator, be cured by surgical resection at the time
             of randomization;

          -  Patients who have failed first line treatment containing fluoropyrimidine and
             oxaliplatin based chemotherapy with or without bevacizumab for mCRC.

        Exclusion Criteria:

        • Prior irinotecan use for the treatment of mCRC.
Clinical trial NCT00658086 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: aln-rsv01, normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Single or bilateral lung transplant recipients

          -  Confirmed RSV infection

          -  Greater than 90 days post current lung transplant

          -  Rejection free for a minimum of 1 month

        Exclusion Criteria:

          -  Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection
             at the time of diagnosis

          -  Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has
             not been stable for at least 3 months

          -  Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or
             thymoglobulin within 3 months of screening: concurrent use of >= 0.3 mg/kg/day
             prednisone or equivalent as maintenance therapy

          -  active treament for acute graft rejection